Navigation Links
bioTheranostics' Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
Date:12/10/2010

would respond to extended therapy with letrozole.  

Data from the study demonstrate that BCI is a prognostic biomarker for late recurrence  among ER-positive breast cancer patients. The data also confirm that HOXB13, part of the Breast Cancer Index, predicted patient benefit from letrozole among ER-positive breast cancer patients.

"For breast cancer patients and the medical professionals who treat them, this is a significant finding," said Dennis Sgroi, MD, Massachusetts General Hospital. "It is our understanding that this is the first time a biomarker has been validated exclusively in the 'late recurrence' setting.  It will be a valuable tool to help identify those patients whose disease will most likely recur, as well as those who will benefit from extended therapy."

"In combination with data from the Stockholm cohort presented at last year's SABCS, the data presented today reinforce BCI's unique prognostic value and application for long-term risk prognosis in the breast cancer setting," said Mark Erlander, PhD, chief scientific officer of bioTheranostics.

About bioTheranosticsAdvancing Molecular Diagnostics in OncologybioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community to support targeted disease management. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index, which provides risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer; and the CancerTYPE ID® test, a cancer classification assay that provides molecular classification of cancers with indeterminate, uncertain, or differential diagnoses to aid in the determination of the
'/>"/>

SOURCE bioTheranostics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
2. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
3. Reportlinker Adds Breast Cancer Drug Futures
4. LCS Constructors, Inc. Supports the Cure and Breast Cancer Awareness Month
5. Leading Journal Turns Up the Heat on Cutting-Edge Breast Cancer Treatment
6. K-State Research Team Investigates Mutated Genes Role in Breast Cancer
7. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
9. Huiheng Medical, Inc. Announces Agreement to Acquire the ClearPath (TM) Breast Brachytherapy System
10. Abviva Details Patent Information for its Breast Cancer Risk Assessment Technology
11. Abviva Announces Further Patent Issuance for Technology Used in Breast Cancer Diagnostics and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 ... leader in Personalized Medicine, is excited to announce ... Response profile . This profile assesses 62 genetic ... provide dosing information for commonly prescribed non-opioid pain ... (brand name Neurontin), alprazolam (brand name Xanax) and ...
(Date:4/23/2015)... , April 23, 2015  Propanc Health ... healthcare company, focuses on the development of cancer ... The company lead product includes PRP, a patented ... and chymotrypsinogen, as well as the enzyme amylase ... also developing a combination of anti-cancer agents working ...
(Date:4/23/2015)... 2015 ReliantHeart's HeartAssist5® Ventricular Assist Device ... through the device) in real time, and this data ... leading provider of Machine to Machine (M2M) communications for ... via VADLink.com can be monitored by a ... in flow below a minimum threshold, the patient can ...
(Date:4/22/2015)... , April 23, 2015  The Heinz Family ... th Heinz Awards, which will present unrestricted ... Americans for their creativity and determination in finding ... This year,s recipients include a prolific ... modern-day life and personal relationships; two former Marines ...
Breaking Biology Technology:Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Early Stage BioTech offers Plenty of Risk; Propanc Health Group Analyst Brief Issued by BrokerBank Securities, Inc. 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6
... Omeros Corporation (NASDAQ: OMER ), ... and commercializing products targeting inflammation, coagulopathies and disorders ... Gregory A. Demopulos, M.D., chairman and chief executive ... and Renshaw 13th Annual Healthcare Conference taking place ...
... , Gains US Patent Protection for Proprietary AAV Intellectual ... leader in the field of human gene therapy, today ... agreement with the US National Institutes of Health (NIH) ... therapy vectors for liver and brain indications. This agreement ...
... This September, during Prostate Cancer Awareness Month , ... method that may change the face of prostate ... and one Boston hospital, analyzed by the National Cancer Institute, ... Dr. David Samadi, Vice Chairman, Department of Urology, and ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 2Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health 3More Precise Prostate Cancer Screening on Horizon 2More Precise Prostate Cancer Screening on Horizon 3
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... New research from The University of Western Ontario leads ... the Arctic Circle during the Pleistocene Epoch (approx. 150,000 ... three years later than modern day African elephants due ... nursing pattern could have contributed to the prehistoric elephant,s ...
... 21, 2010 Reportlinker.com announces that a new market ... Indian Biometric Market http://www.reportlinker.com/p0351944/Indian-Biometric-Market.html ... fastest emerging technology in the Indian Securities & Identification ... many conventional methods of Identity & Security checks like, ...
... Miscanthus x giganteus is the forerunner in the ... researchers believe "putting all their eggs in one basket" could ... recently reported the first natural occurrence in several decades of ... M. x giganteus is the only variety available, ...
Cached Biology News:Being good moms couldn't save the woolly mammoth 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 2New Miscanthus hybrid discovery in Japan could open doors for biofuel industry 3
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: